Last update 12 Dec 2024

BI-1206

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
6G 11, 6G-11, BI 1206
+ [1]
Target
Mechanism
CD32B antagonists(Low affinity immunoglobulin gamma Fc region receptor II-b antagonists)
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
RegulationOrphan Drug (US)
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Non-Hodgkin LymphomaPhase 2
GB
30 Jan 2022
Advanced Malignant Solid NeoplasmPhase 2
US
29 Jun 2020
Advanced Malignant Solid NeoplasmPhase 2
US
29 Jun 2020
Advanced Malignant Solid NeoplasmPhase 2
SE
29 Jun 2020
Advanced Malignant Solid NeoplasmPhase 2
SE
29 Jun 2020
Solid tumorPhase 2
US
29 Jun 2020
Solid tumorPhase 2
SE
29 Jun 2020
B-Cell LymphomaPhase 2
US
16 May 2018
B-Cell LymphomaPhase 2
PL
16 May 2018
B-Cell LymphomaPhase 2
ES
16 May 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
15
BI-1206 IV
ourqsrbeit(pbeoicjylc) = The most frequent related adverse events were infusion-related reactions, thrombocytopenia and elevated liver enzymes. All were transient without any clinical consequences, and adequate pre-medication with corticosteroids or split dose administration reduced the risk and/or intensity of these events. cttycncogy (idhefkgpwo )
Positive
24 May 2024
EHA2024
ManualManual
Phase 1/2
-
cdehriqtry(btwkmvcdft) = the most frequent related treatment-emergent adverse events after BI-1206 IV wasthrombocytopenia and elevated transaminases. Thrombocytopenia ≥G3 occurred in 4 out of 10 subjectswithout premedication and 6 out of 13 subjects with premedication. No associated bleeding occurred. Allevents were resolved with a median duration of 5 days. Elevated liver enzymes ≥G3 occurred in 4 out of 10subjects without premedication and 3 out of 13 subjects with premedication. Events were resolved with amedian duration of 4 days without any clinical complication. xbapmiacyy (dtbdxhygfh )
Positive
14 May 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free